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EPR studies of intermolecular interactions
and competitive binding of drugs in a drug–BSA
binding model†
Y. Akdogan,*a M. Emrullahoglu,b D. Tatlidil,a M. Ucuncub and G. Cakan-Akdoganc
Understanding intermolecular interactions between drugs and proteins is very important in drug delivery
studies. Here, we studied different binding interactions between salicylic acid and bovine serum albumin
(BSA) using electron paramagnetic resonance (EPR) spectroscopy. Salicylic acid was labeled with a stable
radical (spin label) in order to monitor its mobilized (free) or immobilized (bound to BSA) states.
In addition to spin labeled salicylic acid (SL-salicylic acid), its derivatives including SL-benzoic acid,
SL-phenol, SL-benzene, SL-cyclohexane and SL-hexane were synthesized to reveal the effects of various
drug binding interactions. EPR results of these SL-molecules showed that hydrophobic interaction is the
main driving force. Whereas each of the two functional groups (–COOH and –OH) on the benzene ring
has a minute but detectable effect on the drug–protein complex formation. In order to investigate
the effect of electrostatic interaction on drug binding, cationic BSA (cBSA) was synthesized, altering the
negative net charge of BSA to positive. The salicylic acid loading capacity of cBSA is significantly higher
compared to that of BSA, indicating the importance of electrostatic interaction in drug binding. Moreover,
the competitive binding properties of salicylic acid, ibuprofen and aspirin to BSA were studied. The
combined EPR results of SL-salicylic acid/ibuprofen and SL-ibuprofen/salicylic acid showed that
ibuprofen is able to replace up to B83% of bound SL-salicylic acid, and salicylic acid can replace only
B14% of the bound SL-ibuprofen. This indicates that B97% of all salicylic acid and ibuprofen binding
sites are shared. On the other hand, aspirin replaces only B23% of bound SL-salicylic acid, and salicylic
acid replaces B50% of bound SL-aspirin, indicating that B73% of all salicylic acid and aspirin binding
sites are shared. These results show that EPR spectroscopy in combination with the spin labeling
technique is a very powerful method to investigate drug binding dynamics in detail.
Introduction
Electron paramagnetic resonance (EPR) spectroscopy is a highly
selective and sensitive method to locally probe paramagnetic
molecules (spin labels or spin probes). The spin labeling technique
makes EPR spectroscopy a powerful method for studying inter-
actions between spin labeled drugs and proteins.1–3 Although
spin labeled drugs have been used in the studies of drug
mechanisms for a long time, the number of EPR studies is still
not sufficient in the field of drug delivery.4–7 The most common
exogenous stable free radicals, Tempo (2,2,6,6-tetramethylpiperidine-
1-oxyl) based nitroxide radicals, are used as spin labels. Information
on the spin label dynamics can be obtained by analyzing the
line shape of the continuous wave (cw) EPR spectrum at room
temperature.8 The rotational dynamics of spin labeled molecules
determines the line shape of the EPR spectrum. Immobilized
drugs (bound) have broad signals coming from restricted rotational
motion. On the other hand, mobilized drugs (free) have three sharp
line signals coming from freely rotational motion.8,9
Different Tempo based nitroxide radicals are commercially
available with various functional groups. These spin labels can
be covalently attached to drugs via their appropriate functional
groups. Therefore, we are able to monitor drugs in a protein
solution using EPR spectroscopy.
Salicylic acid, acetyl salicylic acid (aspirin) and ibuprofen are
non-steroidal anti-inflammatory drugs that can bind to bovine
serum albumin (BSA) efficiently with 104–106 M1 binding
constants.10,11 Serum albumin is the main binding protein in
blood plasma for a large number of drugs. Mostly, drugs bind to
serum albumin at one of two primary sites (site I and site II).12
Therefore, co-administration of drugs causes a competition for
the binding sites of serum albumin. A drug with a higher
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affinity can replace a bound drug with a lower affinity to serum
albumin. Therefore, the level of active (free) drug changes in the
presence of a second drug, which is crucial to the therapeutic
effect of drugs.13
Our study consists of two parts. In the first part, intermolecular
interactions between salicylic acid and BSA were studied. In the
second part, we showed that EPR spectroscopy can be used as
an alternative technique to study the competitive binding of
drugs to serum albumin.
Usually drug/protein binding is a reversible process. For
reversible binding, the drug binds to a protein with several
weak chemical bonds such as electrostatic interactions, hydrogen
bonds, hydrophobic forces and van der Waals interactions.14
Here, the effects of these intermolecular interactions on the
binding process were studied using synthesized SL-salicylic
acid, SL-benzoic acid, SL-phenol, SL-benzene, SL-cyclohexane
and SL-hexane by EPR spectroscopy (Fig. 1).
In the second part of the study, we used EPR spectroscopy to
make an analysis of the competitive binding of ibuprofen–
salicylic acid and aspirin–salicylic acid to BSA. Several techniques
have been used to study the competitive binding of drugs to
serum albumin including gel filtration techniques, equilibrium
dialysis, NMR spectroscopy and fluorescence spectroscopy.15–18
Kuchimanchi et al. studied the binding of cosalane to BSA in the
presence of salicylic acid by a gel filtration technique.15 Sakai et al.
observed the competitive interaction between indoxyl sulfate
and dansyl-L-asparagine to the N-conformer of human serum
albumin (HSA) by equilibrium dialysis.16 Cui et al. analysed the
competitive binding of ibuprofen and salicylic acid to HSA by
NMR relaxation measurements.17 The observed 1H relaxation
rate of drugs was regarded as a weighted average of that of the
free and bound forms of drugs. Among the techniques used in
drug binding studies, fluorescence spectroscopy has been used
frequently. The presence of intrinsic fluorescence active sites in
serum albumin (tryptophan, tyrosine and phenylalanine) makes
the fluorescence spectroscopy technique very convenient for
drug binding studies. Also, external site marker fluorescence
probes for binding sites (warfarin, dansylamide, dansyl-L-asparagine,
ibuprofen, etc.) have been used to characterize binding sites and
their affinity towards drugs.18–21
As an alternative technique, we used cw EPR spectroscopy to
monitor bound and unbound (free) drugs simultaneously at
physiological albumin concentrations. The calculated areas
under the bound and free signals give their concentrations
separately. Therefore, the change in the bound and free con-
centrations of a drug can be monitored easily in the presence of
another type of drug. This provides information about the
association constants of drugs and also their shared binding sites.
Experimental
Reagents
Bovine serum albumin (fatty acid free), Tempo-4-amino (97%),
4-amino salicylic acid (99%), 4-amino benzoic acid (99%),
3-amino phenol (98%), phenyl isothiocyanate (97%), cyclohexyl
isothiocyanate (98%), hexyl isothiocyanate (95%), ibuprofen
(98%), acetyl salicylic acid (99%), N-(3-dimethylaminopropyl)-
N0-ethylcarbodiimide hydrochloride (EDC, 98%), hydrochloric acid
(37%, 12.2 M), dichloromethane (99.8%), trimethylamine (99.5%),
ethyl acetate (99.5%), methanol (99.8%) were purchased from
Sigma-Aldrich. Thiophosgene (99%) was purchased fromMerck.
Synthesis of SL-molecules
The mechanisms of synthesis of SL-molecules and their EPR
spectra in buffer solutions are shown in Fig. S1 and S2 (ESI†),
respectively.
Spin labeled salicylic acid (SL-salicylic acid). 4-Amino salicylic
acid (0.01 mol) was dissolved in 32 mL water and then acidified
with 3.4 mL HCl (12.2 M). Thereafter, thiophosgene (0.044 mol)
was introduced. After stirring for 1 hour at 0 1C, the solution was
stirred for 2.5 hours at 25 1C. The solution was filtered and dried
under vacuum.22 The yield is 50%. Tempo-4-amino (0.625 mmol)
and 4-isothiocyanate salicylic acid (0.46 mmol) were dissolved in
20 mL DCM. A few drops of triethylamine were added and stirred
overnight at 25 1C. SL-salicylic acid was purified by column
chromatography (ethyl acetate :methanol, 15 : 1, 13 : 1, 12 : 1 and
10 : 1). The yield is 46%.
Spin labeled benzoic acid (SL-benzoic acid). 4-Amino benzoic
acid (0.01 mol) was used as a starting chemical and the
procedure of synthesis of SL-salicylic acid was applied. The yield
of 4-isothiocyanate benzoic acid is 50%. Tempo-4-amino
(0.625 mmol) and 4-isothiocyanate benzoic acid (0.46 mmol)
were dissolved in 10 mL DCM. 10 drops of triethylamine were
added and stirred for 2 days at 25 1C. SL-benzoic acid was
purified by column chromatography (hexane : ethyl acetate 4 : 1
and 3 : 1). The yield is 25%.
Fig. 1 Chemical structures of spin labeled (SL) molecules: (A) SL-salicylic
acid, (B) SL-benzoic acid, (C) SL-phenol, (D) SL-benzene, (E) SL-cyclohexane,
(F) SL-hexane, (G) SL-methane, (H) SL-aspirin and (I) SL-ibuprofen. Tempo
based nitroxide radical: (J) 4-amino Tempo.
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Spin labeled phenol (SL-phenol). 3-Amino phenol (0.01 mol)
was dissolved in 32 mL water and then acidified with 3.4 mL
HCl (12.2 M). Thereafter, thiophosgene (0.044 mol) was introduced.
After stirring for 1 hour at 0 1C, the solution was stirred for 2.5 hours
at 25 1C. This was followed by extraction with saturated 3-isothio-
cyanate phenol solution and saturated dichloromethane (3 
30 mL) to remove starting materials and by-products. The
organic solvent was removed by rotary evaporation and dried
under vacuum. The yield is 45%. Tempo-4-amino (0.625 mmol)
and 3-isothiocyanate phenol (0.46 mmol) were dissolved in 10 mL
DCM. A few drops of triethylamine were added and stirred for 2 days
at 25 1C. SL-phenol was purified by flash column chromatography
(hexane :ethyl acetate 4 :1, 3 :1 and 2 :1). The yield is 37%.
Spin labeled benzene (SL-benzene).Tempo-4-amino (0.625mmol)
and phenyl isothiocyanate (0.46 mmol, 55 mL) were dissolved in
10 mL DCM. 7 drops of triethylamine were added and stirred
overnight at 25 1C. SL-benzene was purified by flash column
chromatography (hexane : ethyl acetate 4 : 1, 3 : 1 and 2 : 1). The
yield is 55%.
Spin labeled cyclohexane (SL-cyclohexane). Tempo-4-amino
(0.625 mmol) and cyclohexyl isothiocyanate (0.46 mmol, 15.3 mL)
were dissolved in 10 mL DCM. A few drops of triethylamine were
added and stirred overnight at 25 1C. SL-cyclohexane was purified
by column chromatography (hexane : ethyl acetate 4 : 1 and 3 : 1).
The yield is 25%.
Spin labeled hexane (SL-hexane). Tempo-4-amino (0.625 mmol)
and hexyl isothiocyanate (0.46 mmol, 13.2 mL) were dissolved in
10 mL DCM. A few drops of triethylamine were added and
stirred overnight at 25 1C. SL-hexane was purified by column
chromatography (hexane : ethyl acetate 4 : 1 and 3 : 1). The yield
is 28%.
Spin labeled methane (SL-methane). Tempo-4-amino
(0.625 mmol) and methyl isothiocyanate (0.46 mmol, 31.5 mL)
were dissolved in 10 mL DCM. A few drops of triethylamine
were added and stirred overnight at 25 1C. SL-methane was
purified by column chromatography (hexane : ethyl acetate 3 : 1
and 2 : 1). The yield is 32%.
Spin labeled ibuprofen (SL-ibuprofen). Tempo-4-amino (0.2 M),
ibuprofen (0.2 M) and 1-ethyl-3-(3-dimethylaminopropyl) carbo-
diimide (EDC) (0.2 M) were mixed in DCM at 1 : 1 : 1 ratio under
argon and stirred for 18 hours at 25 1C. SL-ibuprofen was
purified with column chromatography (hexane : ethyl acetate
5 : 1, 4 : 1, 3 : 1 and 2 : 1). The yield is 69%.
Spin labeled aspirin (SL-aspirin). Tempo-4-amino (0.2 M),
aspirin (0.2 M) and 1-ethyl-3-(3-dimethylaminopropyl) carbodi-
imide (EDC) (0.2 M) were mixed in DCM at a 1 : 1 : 1 ratio under
argon and stirred for 18 hours at 25 1C. SL-aspirin was purified
by column chromatography (hexane : ethyl acetate 4 : 1, 3 : 1 and
2.3 : 1). The yield is 58%.
Preparation of cHSA
Cationization of BSA was achieved by applying a procedure that
has been reported previously.23 BSA (50 mg, 0.15 mmol) was
dissolved in 5 mL ethylenediamine aqueous solution (50 mM,
pH: 4.75) at 25 1C. After that N-(3-dimethylaminopropyl)-N0-
ethylcarbodiimidehydrochloride (410mg, 2.1mmol) was introduced.
After stirring for 2 hours at 25 1C, the reaction was stopped by
adding acetate-buffer (360 mL, 4 M, pH: 4.75). The colorless
solution was concentrated by ultrafiltration (Amicon Ultra
50 kDa MWCO), washed three times with acetate-buffer (100 mM,
pH: 4.75) and five times with Milli-Q water. The yield of the
experiment was 95%. A Malvern dynamic light scattering (DLS)
Nano-ZS instrument was used for zeta potential measurements.
Binding of spin labeled molecules to BSA and to cBSA
Aqueous solutions of BSA and cBSA at different concentrations
were prepared in 0.1 M phosphate buffer (pH 7.4). One of the
most common buffers used in biological reactions is phosphate
buffer (pKa = 6.8). The buffering range of phosphate buffer
(pH = pKa  1) matches the pH of mammalian cells (pH = 7.35–
7.45) with a lack of toxicity. Also, phosphoric acid and dihydrogen
phosphate ions are found in the blood at very low concentrations.24
The SL-molecule stock solution (1 M) was prepared in DMSO. The
desired ratio of spin labeledmolecules to BSA was obtained with the
addition of the appropriate amount of spin labeled molecule
solution to the protein solution with constant stirring. The
concentrations (0.5–0.7 mM) of used drugs are similar to
the typical concentrations of drugs in the blood plasma. In
the literature, Morra et al.25 reported that the serum concentra-
tions of salicylic acid were between 0.2 mM and 0.66 mM, and
Janssen et al.26 showed that the mean plasma concentration
of ibuprofen was 0.4 mM. The DMSO concentration was kept
below 1% (v/v). The solution was allowed to equilibrate at 37 1C
for 10 min for EPR measurements.
EPR measurements
A CMS 8400 (Adani) benchtop spectrometer provided with a
TE102 resonator cavity was used for all X-band EPRmeasurements
at a microwave frequency of B9.4 GHz at 25 1C. Measurements
were performed in quartz capillary sample tubes. The shown EPR
spectra were normalized to the intensity of the high field line of
the unbound spin labeled molecules. All spectra were simulated
using the Matlab-based Easyspin 4.5.5 software package.27
Results and discussion
In this study, we tried to mimic in vivo conditions such as the
physiological concentrations of albumin, the pH value of blood,
buffer and also the body temperature. We studied mainly the
physiological concentrations of albumin (0.5–0.7 mM). The pH
value was kept constant at 7.4 just like the pH value of blood
using phosphate buffer. Phosphate buffer is a nontoxic buffer
and its buffering range is appropriate for the pH value of blood.
Finally, we mixed the drug and albumin at a body temperature
of 37 1C about 10 minutes. Therefore, the experimental conditions
are close to the conditions in vivo.
Analysis of bound and free drugs by EPR spectroscopy
Cw EPR spectroscopy allows us to obtain bound and free spin
labeled dugs simultaneously in the physiological range of
albumin (0.5–0.7 mM). In solution, analysis of the EPR spectral
PCCP Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
5 
Ju
ly
 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
7/
07
/2
01
7 
11
:4
3:
08
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
22534 | Phys. Chem. Chem. Phys., 2016, 18, 22531--22539 This journal is© the Owner Societies 2016
line shape reveals the rotational behaviour of the spin labeled
molecules. The rotational motion of molecules is strongly affected
by macromolecule binding. Therefore, rotational correlation time
increases from the ps to ms range depending on the immobilization
strength.
Fig. 2 shows the EPR spectrum of 0.6 mM SL-salicylic acid in
buffered solution of 0.6 mM BSA (1 : 1) with the corresponding
simulation. The simulations of bound and free (unbound)
SL-salicylic acid were added with the calculated proportions
giving the experimental result. At room temperature, protein
bound spin labeled drugs show broad outer hyperfine signals
due to restricted rotational motion (10 ns), and free spin
labeled drugs show three sharp signals (0.07 ns), signatures
of the freely tumbling motion of radicals. The area under each
signal (by double integration of EPR spectrum) of the simulated
EPR spectra of bound and unbound SL-salicylic acid reveals the
ratio of bound to unbound drugs, e.g. the ratio is B5 : 1 of
0.6 mM SL-salicylic acid/BSA (1 : 1) solution.
Intermolecular interactions of SL-salicylic acid and BSA
Hydrophobic interactions, electrostatic interactions, hydrogen
bonding and van der Waals interactions determine the extent
of binding of drugs to serum albumin.14 Here, we study the
effect of these intermolecular interactions on the binding of
salicylic acid to albumin individually by EPR spectroscopy. In
our previous study, we showed that SL-salicylic acid binds to
albumin by 80% at physiological concentrations.3 Salicylic acid
has a phenyl group and two functional groups, a hydroxyl group and
a carboxylic acid group. At pH 7.4 salicylic acid carries a negative
charge on the carboxylate group (pKa = 2.97) and contains a
hydrogen bond forming group (hydroxyl group). The aromatic group
of salicylic acid may interact with other aromatic rings in albumin
forming pi–pi stacking in addition to hydrophobic interactions.
Fig. 1 shows chemical structures of spin labeled molecules
used in this study. SL-salicylic acid has two functional groups
(–COOH and –OH) but SL-benzoic acid and SL-phenol have only
the –COOH group and the –OH group, respectively. Although
SL-benzene and SL-cyclohexane do not have these functional
groups, SL-benzene conserves aromaticity but SL-cyclohexane
does not.
Therefore, we can control the pi–pi stacking effect on the
formation of a drug-albumin complex by comparing the results
of SL-benzene and SL-cyclohexane. The polarity of these molecules
is also different. Salicylic acid with two functional groups is expected
to be more polar than others. Benzene without two functional
groups must be less polar than salicylic acid, benzoic acid and
phenol. The polarity of cyclohexane is similar to benzene but it
does not have aromaticity. In addition to them, we also synthe-
sized SL-hexane which is more hydrophobic than the others.28
The uptake of spin labeled molecules by BSA is shown in
Fig. 3(A). The EPR spectra are normalized to the intensity of the
high field line of the unbound molecule which is the least
affected signal by the presence of bound signals of SL-molecules.
Simulations of each spectrum of 0.6 mM SL-salicylic acid,
SL-benzoic acid, SL-phenol, SL-benzene and SL-cyclohexane in
0.6 mM BSA solutions showed that these molecules extensively
bind to albumin with bound fractions of 0.84–0.76 (Fig. 3(B)).
Since each molecule has a hydrophobic fragment, such as a
benzene ring and a cyclohexane ring, these hydrophobic fragments
are thought to cause the main effect on the formation of a strong
similarmolecule–albumin complex (0.84–0.76). In order to study the
hydrophobic effect on protein binding, we also measured the
SL-hexane/BSA complex. Most of the SL-hexane molecules are
bound to BSA with a fraction of bound SL-hexane as 0.90. Since
SL-hexane is more hydrophobic than the others with its aliphatic
hexyl chain, the fraction of bound SL-hexane is higher than those
of other SL-molecules.
Nevertheless, these molecules have different bound to
unbound molecule ratios with BSA because of their structural
differences. Although SL-salicylic acid, SL-benzoic acid, SL-phenol
and SL-benzene all have an aromatic benzene ring, the number
Fig. 2 Determination of the bound fraction of spin labeled salicylic acid
(SL-salicylic acid) in 0.6 mM BSA solution (1 : 1). Simulations of bound (A)
and free (B) SL-salicylic acid fractions with appropriate proportions yield
the experimental result (C).
Fig. 3 (A) Cw EPR spectra of 0.6 mM SL-molecules in BSA solutions (1 : 1),
(B) fractions of bound SL-molecules obtained from simulations of spectra
from (A): (a) SL-salicylic acid, (b) SL-benzoic acid, (c) SL-phenol,
(d) SL-benzene, (e) SL-cyclohexane and (f) SL-hexane.
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of functional groups on the molecules is different. SL-salicylic
acid binds to BSA slightly more than both SL-benzoic acid and
SL-phenol, and evidently more than SL-benzene. The fractions
of bound SL-salicylic acid, SL-benzoic acid, SL-phenol, and
SL-benzene are 0.84, 0.82, 0.82 and 0.77, respectively. The presence
of –COOH and –OH groups on the benzene ring increases the
bound ratio slightly in the order of SL-benzeneo SL-phenolE
SL-benzoic acid o SL-salicylic acid. This indicates that the
presence of a negative charge carrying group (–COOH) and
hydrogen bond forming groups (–COOH and –OH) promotes
albumin binding.
Another structural factor which is known to promote protein
binding is pi–pi stacking. Comparison of SL-benzene/BSA
and SL-cyclohexane/BSA spectra shows that SL-benzene and
SL-cyclohexane bind to BSA very similarly. The fractions of
bound SL-benzene and SL-cyclohexane are 0.77 and 0.76,
respectively. Since their polarities are similar28 and pi–pi stacking
is only possible for SL-benzene and not for SL-cyclohexane, these
results show that the presence of a pi–pi stacking interaction
between SL-benzene and albumin does not have considerable
effect on protein binding.
Furthermore, the release profiles of SL-salicylic acid and
its spin labeled derivatives (SL-benzoic acid, SL-phenol and
SL-benzene) from BSA were studied by EPR spectroscopy
(Fig. S3, ESI†). 0.5 mM SL-molecules/BSA (1 : 1) solutions were
placed in 3 mL D-tube dialyzers (MWCO 6–8 kDa) and at pre-fixed
times 7 mL samples were removed and measured by EPR spectro-
scopy. Each time both bound and unbound SL-molecules in
albumin solution were detected simultaneously. The EPR line
intensities of the SL-molecules coming from both the bound and
free fractions decrease gradually. Therefore, the bound fractions
of SL-molecules do not change with time in BSA solutions. At
37 1C the relative diffusion rates of SL-salicylic acid and its
derivatives are very similar in the SL-molecules/BSA (1 : 1)
solution (Fig. S3, ESI†). This indicates that the release profiles
of SL-salicylic acid and its spin labeled derivatives (SL-benzoic
acid, SL-phenol and SL-benzene) from BSA are comparable
because of having similar binding interactions with BSA.
Taking the EPR results together, we conclude that hydro-
phobic interaction is the main force between salicylic acid and
BSA. The presence of two functional groups (–COOH and –OH)
on the benzene ring has a minute but detectable effect on the
formation of drug–protein complexes.
As a control experiment, SL-methyl was synthesized and a
mixture of SL-methyl and BSA solution was measured by EPR
spectroscopy (Fig. S4, ESI†). Since methyl has a very low
hydrophobicity compared to hexane, SL-methyl did not bind
to albumin and only three sharp signals coming from free
SL-methyl were obtained. Moreover, Tempo-4-amino was also
mixed with BSA and measured by EPR spectroscopy (Fig. S4,
ESI†). Again, only three sharp signals were observed, signatures
of free radicals.
Comparison of SL-salicylic acid binding to BSA and to cBSA
Cationic albumin was prepared in order to observe the effect of the
net charge of albumin on drug binding. Albumin cationization was
achieved by following the procedure that has been previously
described.23 The negative net charge (19  2) on the BSA
was converted into a positive net charge (+23  3) after the
reaction of BSA with ethylenediamine at pH 4.75. The uptake of
0.6 mM SL-salicylic acid by 0.6 mM cBSA was monitored by EPR
spectroscopy (Fig. 4(A)). The bound fraction of SL-salicylic acid
increases from 0.84 to 0.89 in BSA and in cBSA, respectively. An
obvious increase in the bound fraction of SL-salicylic acid can
be explained by the presence of electrostatic attraction between
SL-salicylic acid and cBSA.23,29
In a previous study, it has been shown that a maximum of 7
SL-salicylic acid molecules can bind to each BSA molecule in
the physiological concentration range.3 In order to find out the
the loading capacity of cBSA, a series of SL-salicylic acid
samples with different concentrations from 0.5 mM to 15 mM
were added to 0.5 mM cBSA solution (Fig. S5, ESI†). In the
normalized EPR spectra, the bound fraction of SL-salicylic acid
decreases with increasing SL-salicylic acid concentration
(Fig. S5, ESI†). Yet, the number of bound SL-salicylic acid per
cBSA increases regularly and does not reach a saturation point
under the experimental conditions (up to 15 mM SL-salicylic
acid) (Fig. 4(B)). This indicates that cBSA at physiological
concentrations has numerous binding sites for SL-salicylic
acid. If we compare the bound fractions of SL-salicylic acid in
BSA and in cBSA solutions, SL-salicylic acid forms a saturated
complex with BSA at a molar ratio of 7 : 1 but each cBSA can
load B20 SL-salicylic acid at a [SL-salicylic acid]/[cBSA] molar
ratio of 30 : 1. The –COOH and –OH functional groups collectively
provide a partial negative charge on SL-salicylic acid. Therefore,
SL-salicylic acid can bind to cBSA with a higher efficiency
Fig. 4 (A) Cw EPR spectra of 0.6 mM SL-salicylic acid in BSA solution
(black) and in cBSA solution (red) at a drug/albumin ratio of 1. (B) The
concentration ratio of bound SL-salicylic acid to BSA saturates (black) with
increasing SL-salicylic acid concentration in a constant 0.5 mM BSA
solution. The concentration ratio of bound SL-salicylic acid to cBSA
increases (red) with increasing SL-salicylic acid concentration in a constant
0.5 mM cBSA solution. (C) The bound SL-salicylic acid release profiles from
BSA and from cBSA with time at 37 1C. The data of SL-salicylic acid/BSA in
(B) and (C) were taken from ref. 3.
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compared to its binding to anionic BSA. Repelling of the negatively
charged drug by anionic BSA can be explained in terms of a
heterogeneous charge distribution on the BSAmolecule. The larger
negative domain of the protein hinders the anionic drug binding
and also prevents it electrostatically from the attractive cationic
domain.30 Furthermore, theoretical studies of polyelectrolyte (PE)
binding onto net-neutral Janus nanospheres (JNSs), with two
equally but oppositely charged hemispheres, support the drug
binding behaviour of BSA.31 PE–JNS adsorption at low salt
concentration is carried out with PE attraction by the oppositely
charged hemisphere and PE repulsion by the similarly charged
hemisphere.
The net charge of albumin also affects the drug release. For
the releasing study, 0.5 mM SL-salicylic acid/cBSA (1 : 1) and
0.5 mM SL-salicylic acid/BSA (1 : 1) solutions were placed in
3 mL D-tube dialyzers (MWCO 6–8 kDa) and at prefixed times
7 mL samples were removed and measured by EPR spectroscopy
(Fig. S6, ESI†). At 37 1C the relative diffusion rate of SL-salicylic
acid in the SL-salicylic acid/cBSA (1 : 1) solution is slower than
the diffusion rate of SL-salicylic acid in the SL-salicylic acid/BSA
(1 : 1) solution (Fig. 4(C)). This can be explained by the relatively
strong attractive forces between cBSA and SL-salicylic acid.
Attractive electrostatic forces between cationic albumin and
anionic SL-salicylic acid slow down the SL-salicylic acid release.
For example, only 30% of bound SL-salicylic acid is released
from c BSA after 6 hours, but in the same time interval 57% of
bound SL-salicylic acid is released from BSA.
Binding of SL-ibuprofen, SL-aspirin and SL-salicylic acid to BSA
In addition to salicylic acid, we also studied ibuprofen and
aspirin by EPR spectroscopy. Spin labels were attached to the
–COOH groups of ibuprofen and aspirin (Fig. 1). Fig. 5(A) shows
the comparison of the EPR spectra of 0.5 mM SL-ibuprofen,
SL-aspirin and SL-salicylic acid in 0.5 mM BSA solutions. Most
of the SL-ibuprofen is bound to BSA with a fraction of bound
SL-ibuprofen as 0.93. But, the bound fractions of SL-salicylic
acid and SL-aspirin are 0.79 and 0.76, respectively which are
lower than the bound fraction of ibuprofen (Fig. 5(B)). The
bound fractions of SL-drugs depend on the serum albumin
concentration (at a drug : BSA ratio of 1). Therefore, the bound
fractions of SL-salicylic acid are 0.84 and 0.79 in 0.6 mM and
0.5 mM BSA solutions, respectively.
In a previous study, we showed that the extent of SL-salicylic
acid/BSA conjugation decreases sharply especially below the
physiological concentrations (Fig. 5(C)).3 Therefore, we emphasized
the importance of the physiological concentration of albumin
for drug delivery. Fig. S7 (ESI†) shows the EPR spectra of
SL-ibuprofen in BSA solution at a SL-ibuprofen/BSA ratio of 1.
For the concentrated solution (3.0 mM of SL-ibuprofen and
BSA), the bound fraction of SL-ibuprofen is 0.99. When the
mixture of SL-ibuprofen/BSA solution (1 : 1) is diluted with
buffer, the fraction of bound SL-ibuprofen decreases only from
0.99 to 0.82 at 3.0 mM and 0.1 mM concentrations, respectively
(Fig. 5(C)). As a result, a significant amount of SL-ibuprofens is
still bound to BSA in the diluted system. On the other hand,
dilution causes a strong release of SL-salicylic acid from BSA,
the fraction of bound SL-salicylic acid decreases from 0.95 to
0.50 at 3.0 mM and 0.1 mM concentrations, respectively.3
The drug–albumin association constants can also be calculated
from the EPR results. Salicylic acid, aspirin and ibuprofen bind
to BSA via noncovalent bonding therefore an equilibrium exists
between the bound and free states of the drugs:
SL-drug + BSA3 SL-drug/BSA complex
The areas under the EPR signals of the bound and free drugs
provide the concentrations of bound and free drugs in the
system. Then, the association constant (Ka) at equilibrium can
be calculated from the following equation:
Ka ¼ ½SL drug=BSAcomplex½SL drug  ½BSA
where [SL-drug] is the concentration of the free drug, [BSA] is the
concentration of free protein, and [SL-drug/BSA complex] is the
concentration of the drug bound to the protein at equilibrium.
The free BSA and free drug concentrations are assumed to be
equal by accepting that one BSA takes up one SL-drug in the
mixture of drug : albumin with a 1 : 1 molar concentration ratio.
At physiological concentrations of albumin (0.5–0.7 mM),
the calculated Ka values of SL-ibuprofen are about 3.8–5.6 
105 M1, while for SL-salicylic acid and SL-aspirin, the Ka values
are about 3.6–4.8  104 M1, and 2.6–3.3  104 M1, respectively.
EPR results show that the binding affinity of SL-ibuprofen to BSA
is B10 times higher than the binding affinities of SL-salicylic
acid and SL-aspirin to BSA.
Ibuprofen is a more hydrophobic molecule compared to
aspirin and salicylic acid; therefore it is not surprising that the
Fig. 5 (A) Cw EPR spectra of 0.5 mM SL-drugs in 0.5 mM BSA solution:
SL-aspirin (black), SL-salicylic acid (red) and SL-ibuprofen (blue). (B) Fractions
of bound SL-drugs obtained from simulations of spectra from (A):
(a) SL-aspirin, (b) SL-salicylic acid, and (c) SL-ibuprofen. (C) Fractions of
bound SL-salicylic acid and SL-ibuprofen obtained from simulations of
EPR spectra of SL-drug/BSA solutions (1 : 1). The concentrations of SL-drug
and BSA decrease from 3.0 mM to 0.1 mM for both drugs. The circle shows
the concentrations of BSA in the physiological range (0.5–0.7 mM BSA).
The data for SL-salicylic acid/BSA in (C) were taken from ref. 3.
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more hydrophobic ibuprofen molecule could bind to BSA
higher than the binding of aspirin and salicylic acid to BSA.
EPR studies of competitive binding of drugs with BSA
In the literature, interactions between small molecules and
biomacromolecules have been extensively studied by X-ray
crystallography.32–34 Structures of several albumin-drug complexes
have also been resolved by X-ray crystallography.35 A 3D structure of
the albumin crystal revealed that the main drug binding sites in
BSA site I and site II are located in the hydrophobic cavities of
sub-domains IIA and IIIA, respectively.12,35 Yang et al. showed
3D structures of both aspirin and salicylic acid bind to HSA at
site I.36 The phenyl group of salicylic acid has mostly hydro-
phobic interactions with the surrounding aminoacids in site
I. Ghuman et al.35 crystallized an ibuprofen–HSA complex and
showed the binding sites of ibuprofen as mainly site II and also
to a small extent site I.
Furthermore, fluorescence studies showed that salicylic acid
primarily binds to site I as well as to a smaller extent to site II of
BSA.20 Site II is the main binding site for ibuprofen and aspirin.19
Also, aspirin binds to BSA to a small extent in site I.19
In addition to these drug high binding sites of BSA, several
low affinity binding sites are also available in BSA.17 Drugs may
also compete for these low affinity binding sites in BSA.
Fig. 6(A) shows the EPR spectra of the SL-salicylic acid/BSA
complex before and after the addition of ibuprofen with different
concentrations. At 0.5 mM SL-salicylic acid/BSA (1 : 1), the bound
fraction of SL-salicylic acid is 0.79. After the addition of ibuprofen,
first the bound fraction of SL-salicylic acid does not change
(up to 4 : 1, ibuprofen : SL-salicylic acid) but then it decreases
sharply to 0.14 (Fig. 6(B)). This shows that ibuprofen first binds
to empty sites and then additional ibuprofens displace the
bound SL-salicylic acid from BSA. Since the association constant
of ibuprofen is higher than that of salicylic acid, ibuprofen can
easily replace the salicylic acid. Combining the knowledge from
the literature and our results, one can speculate that SL-salicylic
acid occupies mainly site I and to a small extent site II.
Ibuprofen primarily binds to the empty side of site II and then
replaces SL-salicylic acid from site II and also most of the
SL-salicylic acid from site I.19,20,35 In contrast, we monitored the
state of SL-ibuprofen in a solution of BSA in the presence of
different amounts of salicylic acid (Fig. 6(C)). At 0.5 mM
SL-ibuprofen/BSA (1 : 1), the bound fraction of SL-ibuprofen is
0.93. After the addition of 0.5 mM and 2.0 mM salicylic acid, an
obvious decrease in the bound fraction of SL-ibuprofen from
0.93 to 0.89 and to 0.84, respectively, is observed.
However, the bound fraction of SL-ibuprofen does not
change excessively after the addition of salicylic acid; e.g., the
bound fraction of SL-ibuprofen reduces only to 0.80 in the
presence of 30 mM salicylic acid (Fig. 6(D)). This result correlates
with the preceding result; the bound fraction of SL-ibuprofen
only reduces from 0.93 to 0.80 because salicylic acid with a lower
association constant cannot replace ibuprofen easily. Salicylic
acid displaces only a part of bound ibuprofens from the very
limited sites which have low Ka values for ibuprofen and high Ka
values for salicylic acid, probably site I.20
We can also find out the percentage of binding sites shared
by salicylic acid and ibuprofen. Since additional ibuprofen
(30 mM) replaces 83% of bound salicylic acid (0.5 mM), the
remaining 17% of bound salicylic acid must either have a higher
association constant with BSA or have different binding sites with
respect to ibuprofen. To solve the remaining 17% of the bound
salicylic acid situation, we used the data obtained from SL-ibuprofen/
salicylic acid measurements. The addition of 30 mM salicylic acid to
a 0.5 mM SL-ibuprofen/albumin (1 :1) solution replaces only 14% of
bound SL-ibuprofen. It means 14% of SL-ibuprofen initially occupies
the places in which salicylic acid has a higher association constant
compared to that of ibuprofen. Therefore, 97% of all sites of salicylic
acid and ibuprofen are shared (83% + 14%).
We also investigate the competitive interaction of salicylic
acid and aspirin. Fig. 7 shows the EPR spectra of 0.5 mM
SL-salicylic acid/aspirin (Fig. 7(A)) and also SL-aspirin/salicylic
acid (Fig. 7(C)) mixtures in 0.5 mM BSA solutions. First, in the
SL-salicylic acid/aspirin mixtures, aspirin concentration increases
from 0.5 mM to 30 mM. The fraction of bound SL-salicylic acid
decreases gradually from 0.79 to 0.61 by increasing the ratio of
aspirin/SL-salicylic acid from 0 to 60 (Fig. 7(B)).
Since the calculated association constant of SL-salicylic acid is
slightly higher than that of SL-aspirin, it is expected that aspirin
would not replace the SL-salicylic acid completely in BSA. The small
amount of replacement of SL-salicylic acid by aspirin can be
explained by the weak binding ability of SL-salicylic acid at site II
and the higher binding ability of aspirin at site II.19,20 The remaining
high proportion of SL-salicylic acid locates probably at site I.19
Second, in the SL-aspirin/salicylic acid mixtures, the addition of
salicylic acid rapidly reduces the bound fraction of 0. 5 mM
SL-aspirin from 0.76 to 0.44 after the addition of 2 mM salicylic
acid. It means that the added salicylic acid directly replaces some
Fig. 6 (A) EPR spectra of 0.5 mM SL-salicylic acid in 0.5 mM BSA solution
in the presence of ibuprofen with different concentrations. (B) The bound
fractions of SL-salicylic acids after the addition of ibuprofen obtained from
the simulated spectra in (A). (C) EPR spectra of 0.5 mM SL-ibuprofen in
0.5 mM BSA solution in the presence of salicylic acid with different
concentrations. (D) The bound fractions of SL-ibuprofen after the addition
of salicylic acid obtained from the simulated spectra in (C).
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SL-aspirin but additional salicylic acid (up to 30 mM) only reduces
the bound fraction of SL-aspirin to 0.38 (Fig. 7(D)). This correlates
with the above results; salicylic acid replaces SL-aspirin easily at site
I but some of the SL-aspirin located at site II is still bound.19,20
The percentage of binding sites shared by salicylic acid and
aspirin can be calculated from the above results. Since additional
aspirin (30 mM) replaces only 23% of the bound salicylic acid
(0.5 mM), the remaining 77% of the bound salicylic acid must
either have a higher association constant with BSA or have different
binding sites with respect to aspirin. The addition of 30 mM
salicylic acid to 0.5 mM SL-aspirin/albumin (1 : 1) solution replaces
50% of the bound SL-aspirin. It means 50% of the bound
SL-aspirin initially occupies the places where salicylic acid has a
higher association constant compared to that of aspirin. Therefore,
73% of all sites of salicylic acid and aspirin are shared (23% + 50%).
The extent of drug transportation is important to determine
the dosage of drugs. In the body, drugs can be transported
either as free floating molecules or as protein bound molecules.
The concentration of free drugs is used to determine the effect
of a drug rather than the protein bound concentration. Instead,
a protein bound drug can escape from fast metabolism, which
is crucial for sustained drug delivery applications. Our EPR results
suggested that when two typical non-steroidal anti-inflammatory
drugs, ibuprofen and salicylic acid, are co-administered, mostly
ibuprofen binds to albumin and salicylic acid floats in the blood.
Therefore, salicylic acid is expected to affect faster or/and be
metabolized faster than ibuprofen.
Conclusions
In this study, we have presented the use of EPR spectroscopy
and the spin labeling (SL) technique in the field of drug binding.
Labeling drugs with stable nitroxide based Tempo radicals allows
monitoring of the state of drugs in protein solution since bound
and free spin labeled drugs have different EPR signals. Moreover,
the areas under these signals give us the concentration of the bound
and free drugs individually.
In the first part of the study, we emphasized the inter-
molecular interactions between salicylic acid and BSA. Therefore,
we have synthesized different derivatives of SL-salicylic acid. In
these derivatives, the functional groups on the salicylic acid and
its aromaticity were changed one by one. EPR measurements of
these SL-molecules in BSA solution showed that hydrophobic
interaction is the main interaction among the intermolecular
interactions. While the bound fractions of these molecules are
very close to each other (0.76–0.84), the EPR technique is able to
differentiate the minute effects of structural variation on protein
binding. Moreover, the importance of electrostatic interactions
was determined using cationic BSA (cBSA) instead of anionic BSA.
SL-salicylic acid with negative charge binds more strongly to
cBSA than to BSA, and the SL-salicylic acid loading capacity of
cBSA becomes greater than that of BSA.
In the second part, we used EPR spectroscopy as an alter-
native technique to study the competitive binding of drugs to
BSA. At physiological concentrations of albumin (0.5–0.7 mM),
the association constants of SL-drugs/BSA calculated from EPR
spectra are 3.8–5.6  105 M1 (SL-ibuprofen), 3.6–4.8  104 M1
(SL-salicylic acid), and 2.6–3.3  104 M1 (SL-aspirin). Since
SL-ibuprofen has ten times higher binding affinity to BSA
compared to the binding affinity of SL-salicylic acid, additional
ibuprofens replaceB83% of the bound SL-salicylic acid. However,
additional salicylic acid replaces only B14% of the bound
SL-ibuprofen. Altogether,B97% of all binding sites of salicylic
acid and ibuprofen are shared. On the other hand, the calculated
association constants of aspirin and salicylic acids with BSA are
very close to each other. Therefore, additional salicylic acids
replace only B50% of the bound SL-aspirin, and additional
aspirin replace only B23% of the bound SL-salicylic acid. This
shows thatB73% of all binding sites of salicylic acid and aspirin
are shared.
Thus, applications of cw EPR spectroscopy in combination
with the spin labeling technique can provide information on
the intermolecular interactions in drug/protein complexes and
on the details of competitive binding of drugs.
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